Pharmacist Assisting at Routine Medical Discharge: Project PhARMD Preeyaporn Sarangarm, PharmD Stanley Snowden, PharmD Lisa Koselke, PharmD Thomas Dilworth, PharmD Matthew London, PharmD Christian Sanchez, PharmD PGY1 Pharmacy Practice Residents University of New Mexico Hospital 1 Background Approximately 20% of patients experience an adverse event after discharge Up to 60% are medication related and preventable Results in costly healthcare utilization Pharmacist discharge counseling has shown mixed results in reducing health care utilization Hospital ED readmissions visits 2 Background The American College of Clinical Pharmacists reviewed the literature between 2001 and 2005 surrounding clinical pharmacy services (CPSs) For every dollar spent on CPSs $4.81 was saved No study has examined the cost-effectiveness of an inpatient pharmacist discharge service Perez A et al. Pharmacotherapy. 2008;28(11): 285e-323e. 3 Background Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) July 2007 Inpatient Prospective Payment System (IPPS) linked to compliance with HCAHPS Patient Protection and Affordable Care Act of 2010 HCAHPS will be one of the measures used to calculate Value-based incentive payments (October 2012) Value-based incentive purchasing Patient perception has a significant effect on hospital income Earnings of $4980 per bed linked to one point gain in satisfaction Patients with higher satisfaction ratings of hospital services are less likely to enter into malpractice suits 4 Background When chronic disease states are treated ineffectively, complications of the disease may lead to increased use of hospital, ED, and other medical resources Medication non-adherence is related to greater morbidity and mortality in chronic disease Estimated to increase healthcare costs by over $170 billion annually in this country Increased adherence has the potential to generate medical savings that more than offset the associated increases in drug costs Benner J, et al. JAMA. 2002;288:455–61. O’Connor PJ. Arch Int Med. 2006;166:1802–4. Sokol MC, et al. Med Care. 2005;43:521–30. Schlenk EA, et al. Futura Publishing Co; 2001:57–70. Miller NH. Am J Med. 1997;102:43– 49. 5 Study Objective Primary Outcome: To evaluate the impact of pharmacist discharge counseling on a combined endpoint of 30-day post-discharge hospital readmissions and ED visits Secondary Outcomes: Determine predictors for readmission/ED visits Describe the number and type of interventions Conduct a cost-benefit analysis Improve patient satisfaction Increase primary medication adherence 6 Methods 7 Methods: Study Design Single center, prospective intervention study Number of patients Historical hospital data: 30-day readmission rate: 12.3% 30-day ED visits: 13.0% A Excludes patients who were subsequently admitted priori power analysis: 292 patients in each study group 33% reduction in the combined endpoint Power=80%, α=0.05 8 Methods: Patient Selection Inclusion criteria: Discharged from internal medicine service English or Spanish speaking Exclusion criteria: Less than 18 years of age Unable or unwilling to receive counseling Discharged to anywhere other than home Planned readmission Previous inclusion into the study 9 Methods: Flow of Patients Study introduction to patient Prior to discharge Control Group: Usual Discharge Care Only Intervention Group: Usual Care plus Counseling by a Pharmacy Resident Survey given and collected Survey given and collected 36-72 hours postdischarge 30 days postdischarge Follow-up Phone Call Review patients for readmissions and ED visits Review patients for readmissions and ED visits 10 Method: Discharge Services Prescription review Medication reconciliation Completeness of prescriptions Duplicative, unnecessary or incomplete therapy Drug interactions Insurance coverage/ability to pick up medications Counseling Medication information and administration Side effects Disease state education 11 Methods: Survey Distribution Upon completion of discharge counseling, patients were given the anonymous English or Spanish survey Patients were then left in their room to fill out the survey without the pharmacist present Surveys were placed within the provided envelope by the patient and collected prior to the patient leaving the hospital Patients unable or unwilling to complete the survey were not included in the analysis 12 Methods: Data Collection Upon discharge: At 30 days post-discharge: Patient demographics Admission information Number of prior readmissions Number of medications at discharge Pharmacist interventions and time spent Number of hospital readmissions or ED visits and reason/diagnosis Medication fill history from the UNMH Outpatient Pharmacy for UNM care patients Cost data: Estimated patient charges for readmissions and ED visits Pharmacist salary plus benefits Converted charges to costs using UNMH cost to charge ratio 13 Methods: Intervention Classification Discontinue drug Therapeutic duplication Medication without indication Adverse drug reaction (ADR) Add drug Untreated condition Prevent or treat ADR Change drug Drug interaction Actual or potential ADR Reverse auto-substitution Bayley BK, et al. Ther Clin Risk Manag. 2007; 3:695-703. Change dosing Incorrect or inappropriate Drug interaction Renal adjustment Hepatic adjustment Allergies Allergy updated or clarified Allergy avoided Incomplete prescription Other 14 Methods: Data Analysis Data was analyzed in SPSS (version 18) Univariate analysis: Chi-square for categorical variables T-test for continuous variables Multivariate analysis: Multiple logistic regression MANOVA Nonparametric Mann-Whitney analysis: U test 15 Results: 30-day Readmission and ED visits Primary Outcome 16 Study Recruitment and Flow 17 Demographics (n=279) Control (n=139) Intervention (n=140) P-value 50.4 (16.5) 49.0 (15.8) 0.48 Male 81 (58.3) 75 (53.6) 0.43 Primary Language: English 129 (92.8) 121 (86.4) 0.08 Characteristic Age, mean (SD), years Ethnicity White, non-Hispanic White, Hispanic African American Native American Other Marital Status Single Married Separated/Divorced/Widower *All values reported as n (%) unless specified otherwise 0.30 43 (30.9) 58 (41.7) 7 (5.0) 25 (18.0) 6 (4.3) 46 (32.9) 55 (39.3) 12 (8.6) 16 (11.4) 11 (7.8) 0.23 79 (56.8) 40 (28.8) 20 (14.4) 90 (64.3) 34 (24.3) 16 (11.4) 18 Demographics (n=279) Characteristic Control (n=139) Intervention (n=140) P-value Current Primary Care Provider 80 (57.8) 84 (60.0) 0.68 Insurance Private Insurance Public Insurance County Provided Healthcare (UNM Care) No Insurance 19 (13.7) 76 (54.7) 27 (19.4) 17 (12.2) 17 (12.1) 45 (32.1) 42 (30.0) 36 (25.7) Length of stay, mean (SD), days 6.1 (5.2) 7.3 (8.1) 0.14 Previous admission (within 1 year), mean (SD) 0.7 (1.5) 0.8 (1.6) 0.62 Charleson co-morbidity index score, mean (SD) 3.3 (2.9) 2.9 (2.8) 0.22 57.4 (94.0) 79.9 (229.0) 0.29 Distance from the hospital, mean (SD), miles *All values reported as n (%) unless specified otherwise <0.001 19 Intervention Group (n=140) Declined (n=23) 16% 30-day Readmissions and ED Visits (Univariate Analysis) Control (n=139) N (%) Combined 30-day readmissions and ED visits 30-day hospital readmission 30-day ED visits Related readmission or ED visit Intervention (n=140) N (%) P-value 24 (17.3) 30 (21.4) 0.34 16 (11.5) 11 (7.9) 20 (14.3) 17 (12.1) 0.49 0.24 19/24 (79.2) 23/30 (76.7) 0.83 21 30-day Readmissions and ED Visits (Multivariate Analysis) Multivariate logistic regression Adjusted for confounders that could potentially influence the outcome Factors No in univariate analysis with p<0.1: sex and insurance difference in readmissions and ED visits OR 1.25 (95%CI 0.67-2.34), p=0.48 22 Conclusion: 30-day Readmissions and ED visits Pharmacist discharge counseling services did not significantly improve 30-day hospital readmissions and ED visits 23 Results: Predictors for Readmission and ED Visits Secondary Outcome 24 Risk Factors for Combined 30-day ED Visits and Readmissions No readmission/ED visit (n=225) Readmission/ED visit (n=54) P value Age, mean (SD), years 49.7 (15.8) 49.5 (17.5) 0.93 Primary care provider 132 (58.7) 32 (59.3) 0.94 Primary Language: English 202 (89.8) 48 (88.9) 0.85 Male 132 (58.7) 24 (44.4) 0.06 Risk factors Insurance status Public Insurance UNM Care Private Insurance No Insurance Marital status Married Single Separated/Divorced Widower 0.93 98 (43.6) 54 (24) 30 (13.3) 43 (19.1) 23 (42.6) 15 (27.8) 6 (11.1) 10 (18.5) 0.14 65 (28.9) 135 (60) 17 (7.6) 8 (3.6) *All values reported as n (%) unless specified otherwise 9 (16.7) 34 (63) 7 (13) 4 (7.4) 25 Risk Factors for Combined 30-day ED Visits and Readmissions Risk factors Ethnicity White Hispanic Black Native American Other No readmission or ED visit (n=225) Readmission or ED visit (n=54) P value 0.19 73 (32.4) 84 (37.3) 15 (6.7) 37 (16.4) 16 (7.1) 16 (29.6) 29 (53.7) 4 (7.4) 4 (7.4) 1 (1.9) 71.4 (186.14) 57.1 (120.98) 0.59 Length of hospital stay, mean (SD) 6.4 (6.35) 7.7 (8.48) 0.20 Previous hospital admissions, mean (SD) 0.6 (1.18) 1.3 (2.40) 0.002 Charlson comorbidity index, mean (SD) 2.9 (2.73) 3.5 (3.21) 0.19 Meds pre reconciliation, mean (SD) 5.3 (5.36) 6.8 (5.30) 0.17 Meds post reconciliation, mean (SD) 5.5 (5.21) 7.3 (5.06) 0.10 Distance from the hospital, mean (SD), miles *All values reported as n (%) unless specified otherwise 26 Multivariate Regression Logistic regression for ED visits and readmissions within 30 days postdischarge Risk factors Previous hospital admissions* No Yes OR 95% CI P value 0.008 -1.26 -1.06-1.49 *Statistically significant (P≤0.05), this regression included risk factors with a P<0.1 (gender, previous hospitalization) 27 Multivariate Regression Readmissions within 30-days Risk factors OR 95% CI P value Length of stay* 1.06 1.01-1.12 0.015 Risk factors OR 95% CI P value Previous hospital admissions* 1.23 1.01-1.48 0.035 Divorced* 5.67 1.42-22.66 0.014 ED visits within 30-days *Statistically significant (P≤0.05), this regression included risk factors with a P<0.1 28 Conclusion: Predictors Hospitalizations in the previous year was a significant predictor for readmissions and ED visits Divorce and previous hospital admissions were predictive of ED visits while length of hospital stay was predictive of readmissions 29 Results: Interventions by Pharmacists Secondary Outcome 30 Intervention Group (n=140) Number of Interventions by Type # % total Type of Intervention 66 33.3% Add drug: untreated condition 29 14.6% Change dosing: incorrect or inappropriate 23 11.6% Discontinue drug: medication without indication 19 9.6% Other intervention 15 7.6% Discontinue drug: therapeutic duplication 12 6.0% Incomplete prescription 12 6.0% Cost-savings or third party intervention 10 5.1% Add drug: prevent or treat adverse drug reaction 12 6.0% Cost-savings or third party intervention 32 Number of Interventions by Type (cont.) # % total Type of Intervention 6 3.0% Change dosing: dosage form or route 4 2.0% Change dosing: renal adjustment 1 0.5% Change drug: drug interaction 1 0.5% Change drug: reverse auto-substitution 1 0.5% Allergy clarified or updated 0 0.0% Change dosing: hepatic adjustment 0 0.0% Change dosing: drug interaction 0 0.0% Allergy avoided 33 Top Interventions By class: Anti-infectives 17.79% Cardiovascular 15.95% Gastrointestinal 12.98% Endocrine 11.66% By medication: Oxycodone: 7 interventions Docusate: 7 interventions Ciprofloxacin, clindamycin, insulin glargine, lisinopril, sulfamethoxazole-trimethoprim: 4 interventions 34 Intervention Acceptance Rate 198 Total number of interventions attempted - 13 Interventions not accepted 185 Total number of accepted interventions 93.4% Intervention acceptance rate 35 Unaccepted Interventions Intervention # unaccepted/total % unaccepted Add drug: Untreated condition 4/66 6.1% Discontinue drug: Medication w/o indication 4/23 17.4% Cost-savings/third-party 2/12 16.7% Change dosing: incorrect 1/29 3.4% Reverse auto-sub 1/1 0% Change dosing: renal 1/4 25% 36 Predictors for Need for Intervention Multivariate logistic regression to identify predictors for ≥ 1 pharmacist intervention Age, sex, ethnicity, language, length of stay, previous admission in past year, having a primary care provider at admission, number of medications, and Charlson score were NOT predictors for intervention 37 Conclusion: Interventions by Pharmacists Nearly 60% of patients discharge prescriptions warranted some change by a pharmacist Majority of interventions (93%) accepted and implemented by physician No predictors for which patients needed most interventions Pharmacy discharge services beneficial to all patients 38 Results: Cost-benefit Analysis Secondary Outcome 39 Cost-Benefit Analysis Net benefit = (CC- CI) Benefit to cost ratio = (CC- CI)/C A ratio greater than 1.0 will demonstrate an overall benefit of the intervention CI = readmission and ED costs, intervention CC = readmission and ED costs, control C = cost of pharmacist intervention 40 Mean Costs per Patient Mean (SD) in dollars All patients Combined readmissions and ED visits Only patients who incurred cost Combined readmissions and ED visits Difference in dollars Control (n=139) Intervention (n=140) (95% CI) $1,897.65 ($5,998.90) $2,859.39 ($10,194.97) $961.74 (-$2,935.04 to $1,011.56) Control (n=24) Intervention (n=30) $10,990.50 ($10,565.96) $13,343.80 ($3,800.43) (95% CI) $2,353.26 (-$10,981.23 to $6,274.72) P value 0.34 P value 0.59 41 Intervention Outlier Analysis Outlier Intervention Mean (SD) Combined cost for readmissions and ED visits in patients who incurred cost $98,042 $13,343.80 ($3,800.43) Initial Length of Stay (days) 56 7.3 (8.1) 42 Mean Costs per Patient Excluding Outlier Mean (SD) in dollars All patients Combined readmissions and ED visits Only patients who incurred cost Combined readmissions and ED visits Difference in dollars Control (n=139) Intervention (n=139) (95% CI) $1,897.65 ($5,998.90) $2,174.62 ($6,210.31) $276.97 (-$1,718.71 to $1,164.77) Control (n=24) Intervention (n=29) (95% CI) $10,990.54 ($10,565.96) $10,423.17 ($10,051.77) $567.37 (-$5,131.50 to $6,266.24) P value 0.71 P value 0.84 43 Intervention Costs Total pharmacist time cost Pharmacist cost plus benefits = $68.14 / hour Total hours = 111.55 hrs Total cost = $7,601.02 Cost per patient $7,601.02 / 140 patients = $54.93 / patient 44 Net Benefit Analysis Net benefit per patient Benefit to Cost Ratio All patients -$961.74 -17.5 All patients who incurred cost -$2,353.26 -42.8 All patients who incurred cost excluding outlier $567.37 10.3 45 Conclusion: Cost-benefit Analysis A pharmacist-run discharge service consisting of medication reconciliation, patient counseling, and a follow up phone call did not reduce readmission and ED visit costs at UNMH A sub-analysis of only patients who incurred cost with the exclusion of an outlier showed a positive benefit to cost ratio resulting from the intervention 46 Results: Patient Satisfaction Secondary Outcome 47 Survey Items 1. Explanation of what your medications are for 2. Explanation of how to take your medications 3. Information the healthcare provider gave you about your problem or condition 4. Information the healthcare provider gave you about possible medication side effects 5. Overall rating of the information you received during discharge 6. Knowledge of the healthcare provider who taught you 7. Friendliness/courtesy of healthcare provider who taught you 8. Answers provided by the healthcare provider to your questions 9. Overall rating of the healthcare provider giving discharge teaching Likert response scale 1=Very Bad, 2=Bad, 3=Fair, 4=Good, 5=Very Good 48 Overall Response Rates 49 Overall Mean Response by Group Type N Mean of Summed Responses (max score 45) Control 76 40.37 Intervention 97 43.14 t P value -3.997 <0.0001 50 Mean Rank by Group Type N Mean Rank Sum of Ranks P value Control Intervention 76 97 72.30 98.52 5495 9556 <0.0001 51 Response Means by Group 52 Conclusion: Patient Satisfaction Overall pharmacist-run discharge counseling services had higher satisfaction scores when compared to the usual discharge services provided at UNMH The largest differences between groups were seen in Items 1, 2, 4 and 5 Item 1 Explanation of what your medications are for Item 2 Explanation of how to take your medications Item 4 Information the healthcare provider gave you about possible medication side effects Item 5 Overall rating of the information you received during discharge 53 Results: Primary Medication Adherence Secondary Outcome 54 Primary Medication Adherence Considered adherent if Picked up medication within 30 days of discharge If did not pick up within 30 days, still considered adherent if Supply of medication at home prior to hospitalization PRN medication Rate of primary adherence Expressed as the number of prescriptions filled divided by the total number of prescriptions written 55 UNM Care Patients 698 patients screened for Project PhARMD 279 patients enrolled In Project PhARMD 71 patients (UNM Care) 66 patients met Inclusion criteria 5 patients excluded (no Rx written) 56 UNM Care Demographics (n=66) Control (n=27) Intervention (n=39) P-value 47.6 (16.8) 47.9 (13) 0.25 Male (%) 18 (66.7) 23 (59) 0.52 Primary Language: English (%) 26 (96.3) 33 (84.6) 0.13 Characteristic Age, mean (SD), years Ethnicity (%) White, Non-Hispanic White, Hispanic African American Native American Asian Other 10 (37) 13 (48.1) 2 (7.4) 2 (7.4) 0 (0) 0 (0) 11 (28.2) 18 (46.2) 4 (10.3) 2 (5.1) 1 (2.6) 3 (7.7) Current Primary Care Provider (%) 15 (55.6) 27 (69.2) 0.63 0.26 57 UNM Care Demographics (n=66) Characteristic Marital Status (%) Single Married Divorced Widower Length of Stay, days (SD) Charlson Co-morbidity Index (%) No Risk Mild Moderate Severe Control (n=27) Intervention (n=39) P-value 0.62 16 (59.3) 6 (22.2) 4 (14.8) 1 (3.7) 26 (66.7) 6 (15.4) 6 (15.4) 1 (2.6) 6.04 (4.01) 9.49 (11.48) 0.09 6 (22.2) 9 (33.3) 5 (18.5) 7 (25.9) 10 (25.6) 12 (30.8) 12 (30.8) 5 (12.8) 0.51 58 Ordered Discharge Prescriptions Control (n=27) Intervention (n=39) P-value 3.58 (1.84) 4.13 (2.4) 0.95 Number of scheduled medications, mean (SD) 3.04 (1.71) 3.49 (2.37) 0.41 Number of PRN medications, mean (SD) 0.54 (0.76) 0.64 (0.87) 0.63 Characteristic Number of medications, mean (SD) 59 Number of Rx’s Primary Adherence by Therapeutic Class 60 Primary Medication Adherence Rate Primary medication adherence rate (mean, %) Control (n=27) Intervention (n=39) 58.5 75.7 61 Mean Rank by Group Type N Mean Rank Sum of Ranks P value Control Intervention 27 39 27.96 36.36 727 1418 0.05 62 Conclusion: Primary Medication Adherence Pharmacist discharge counseling services yielded a higher primary medication adherence rate in intervention group Rates of primary adherence between groups trending toward statistical significance Intervention group primary adherence rate similar to that seen in literature for primary care 63 Discussion 64 Limitations Study underpowered to detect a difference Excluded patients that would have potentially benefitted Discharged to outside facilities or left hospital prior to counseling Discharge procedure not standardized between pharmacists Patients may have been readmitted to other hospitals Use of estimated costs rather than actual costs Pharmacist interventions were not associated with a cost-savings value Only evaluated primary medication adherence for UNM Care patients A priori power analysis not reflective of study population Low historical readmission rate Patients could have filled at other pharmacies Potential for selection bias with survey response Health literacy was not assessed No factor analysis conducted to validate survey items 65 Discussion Study highlighted areas for possible improvement in the discharge process Identifying risk factors for hospital readmissions and ED visits may: Pharmacist intervention earlier in hospital stay may improve outcomes Patient counseling may have increased patient knowledge of disease state(s) Identify patients that would benefit most from discharge counseling Create more patient interaction opportunities for pharmacists Patients satisfaction with the service is high Overall satisfaction rates were high with discharge services in both groups Patients had higher satisfaction with discharge services when pharmacist provided counseling in addition to the usual care 66 Future Research Additional studies need to be done to assess Pharmacist impact on readmissions and ED visits in a broader population Predictors for readmissions and ED visits in a broader patient population More rigorous studies are needed to examine the effects of pharmacist interventions on readmission and ED visit costs given previous studies demonstrating the cost-effectiveness of CPSs 67 Acknowledgements Gretchen Ray, PharmD, PhC, BCPS Richard D’Angio, PharmD, BCPS Residency Committee, University of New Mexico Hospital and College of Pharmacy Peggy Beeley, MD Department of Internal Medicine, University of New Mexico Hospital 68